TD Cowen Maintains Buy on Iovance Biotherapeutics, Raises Price Target to $10

Benzinga · 3d ago
TD Cowen analyst Nicholas Lorusso maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and raises the price target from $7 to $10.